How did BSX's Q4 2024 earnings surprise investors?

Boston Scientific's (BSX) Q4 2024 earnings report exceeded investor expectations in several key metrics, reflecting the company's robust performance and growth prospects:

1. **Earnings Per Share (EPS)**:
- Reported EPS was $0.70, surpassing analyst expectations of $0.66.
- This marked a significant year-over-year increase, indicating improved profitability.
2. **Revenue**:
- Total revenue for the quarter was $4.56 billion, exceeding the consensus estimate of $4.42 billion.
- This represented a substantial year-over-year growth, showcasing the company's strong sales momentum.
3. **Segmental Performance**:
- The cardiovascular segment experienced a notable boost, with sales jumping about 29% to $2.94 billion.
- The MedSurg segment also saw revenue rise by 12% to $1.62 billion.
4. **Regional Growth**:
- Sales in the largest geographic region, the US, advanced by approximately 31%.
- This regional strength contributed significantly to the overall revenue outperformance.
5. **Organic Growth**:
- Organic growth, adjusted for foreign currency fluctuations and recent acquisitions/divestitures, was reported at 19.5%.
- This organic growth highlights the company's internal strength and product portfolio effectiveness.

Overall, BSX's Q4 2024 earnings exceeded expectations due to strong revenue growth across key segments and regions, along with improved profitability. These factors combined to create a positive earnings surprise for investors.